Vitreoretinal lymphoma: Central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration

Eye ◽  
2022 ◽  
Author(s):  
Lauren A. Dalvin ◽  
Jose S. Pulido ◽  
Carol L. Shields ◽  
Alessandro Marchese ◽  
Elisabetta Miserocchi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Lymphoma ◽  
Vitreoretinal Lymphoma ◽  
Lymphoma Risk

scholarly journals Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium

2011 ◽  
Vol 16 (11) ◽  
pp. 1589-1599 ◽  
Author(s):  
Chi‐Chao Chan ◽  
James L. Rubenstein ◽  
Sarah E. Coupland ◽  
Janet L. Davis ◽  
J. William Harbour ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Lymphoma ◽  
Collaborative Group ◽  
Primary Vitreoretinal Lymphoma ◽  
Vitreoretinal Lymphoma

scholarly journals Autoimmune conditions and primary central nervous system lymphoma risk among older adults

2019 ◽  
Vol 188 (4) ◽  
pp. 516-521 ◽  
Author(s):  
Parag Mahale ◽  
Megan M. Herr ◽  
Eric A. Engels ◽  
Ruth M. Pfeiffer ◽  
Meredith S. Shiels
Keyword(s):  
Older Adults ◽  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Lymphoma ◽  
Autoimmune Conditions ◽  
Lymphoma Risk

scholarly journals Primary Vitreoretinal Lymphoma Masquerading as Refractory Retinitis

2015 ◽  
Vol 6 (3) ◽  
pp. 345-350 ◽  
Author(s):  
Ofira Zloto ◽  
Amir E. Abd Elkader ◽  
Ido Didi Fabian ◽  
Vicktoria Vishnevskia-Dai
Keyword(s):  
Central Nervous System ◽  
Polymerase Chain Reaction ◽  
Nervous System ◽  
Central Nervous System Lymphoma ◽  
Chain Reaction ◽  
Varicella Zoster ◽  
Primary Vitreoretinal Lymphoma ◽  
Clinical Presentations ◽  
Vitreoretinal Lymphoma ◽  
Polymerase Chain

Purpose: To report a case of a patient with primary vitreoretinal lymphoma masquerading as retinitis. Methods: Retrospective review of the patient's clinical, histopathological and imaging records. Results: Cytopathology was negative for malignancy, and preliminary polymerase chain reaction results supported the diagnosis of varicella zoster virus retinitis. Therefore, the patient was treated with antiviral therapy. However, under this treatment, the retinitis progressed. As a result, primary vitreoretinal lymphoma was suspected, and empirical treatment with intravitreal methotrexate injections was started. Under this treatment, the ocular features improved. Five months after initial ocular presentation and ocular resolution, the patient presented with central nervous system lymphoma. Conclusion: This case should raise the awareness of the variable clinical presentations, the challenging diagnosis and treatment of primary vitreoretinal lymphoma. All cases should be continuously systemically evaluated.

scholarly journals Vitreoretinal Lymphoma

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3921
Author(s):  
Bianka Sobolewska ◽  
Soon-Phaik Chee ◽  
Fatma Zaguia ◽  
Debra Anne Goldstein ◽  
Justine R. Smith ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
External Beam Radiotherapy ◽  
Treatment Protocol ◽  
Central Nervous System Lymphoma ◽  
B Cell Lymphoma ◽  
High Dose ◽  
Cns Involvement ◽  
Intravitreal Chemotherapy ◽  
Vitreoretinal Lymphoma

Vitreoretinal lymphoma (VRL) is a rare variant of primary central nervous system lymphoma (PCNSL), mostly of diffuse large B cell lymphoma, which affects the retina and/or the vitreous with or without optic nerve involvement. The disease course is aggressive. Up to 90% of the patients develop central nervous system lymphoma within one year. The diagnosis of VRL is challenging due to nonspecific chronic and relapsing uveitis and is made by anterior chamber tab or vitreous aspirate biopsy. There is no established treatment protocol for VRL patients with bilateral involvement without CNS involvement. There are suggestions to use only intravitreal chemotherapy with methotrexate and/or rituximab. Alternatively, systemic high-dose MTX treatment or external beam radiotherapy is used. Further studies are needed to prove and confirm the prophylactic systemic therapy in preventing CNS involvement in limited VRL.

Sign in / Sign up

Export Citation Format

Share Document